Chitosan and silver nanoparticles: promising anti-toxoplasma agents.
暂无分享,去创建一个
T. Shalaby | R. Mady | M. Gaafar | R. Diab
[1] Xing-Quan Zhu,et al. DNA immunization with eukaryotic initiation factor-2α of Toxoplasma gondii induces protective immunity against acute and chronic toxoplasmosis in mice. , 2013, Vaccine.
[2] M. Fakhar,et al. In vitro treatments of Echinococcus granulosus with fungal chitosan, as a novel biomolecule. , 2013, Asian Pacific journal of tropical biomedicine.
[3] M. Rafailovich,et al. Investigation of antileishmanial activities of Tio2@Ag nanoparticles on biological properties of L. tropica and L. infantum parasites, in vitro. , 2013, Experimental parasitology.
[4] F. Ahmad,et al. Improved antifilarial activity of ivermectin in chitosan–alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi , 2013, Parasitology Research.
[5] Cara L. Wilhelm,et al. TLR-independent neutrophil-derived IFN-γ is important for host resistance to intracellular pathogens , 2013, Proceedings of the National Academy of Sciences.
[6] Haifang Wang,et al. Evaluation of the adjuvant effect of silver nanoparticles both in vitro and in vivo. , 2013, Toxicology letters.
[7] G. Xie,et al. A novel immunosensor for detecting toxoplasma gondii-specific IgM based on goldmag nanoparticles and graphene sheets. , 2013, Colloids and surfaces. B, Biointerfaces.
[8] Sabyasachi Das,et al. Synthesis, characterization of chitosan-tripolyphosphate conjugated chloroquine nanoparticle and its in vivo anti-malarial efficacy against rodent parasite: a dose and duration dependent approach. , 2012, International journal of pharmaceutics.
[9] Haliza Katas,et al. Antifungal Activity of Chitosan Nanoparticles and Correlation with Their Physical Properties , 2012, International journal of biomaterials.
[10] F. Robert-Gangneux,et al. Epidemiology of and Diagnostic Strategies for Toxoplasmosis , 2012, Clinical Microbiology Reviews.
[11] Y. Gohar,et al. Validity of silver, chitosan, and curcumin nanoparticles as anti-Giardia agents , 2012, Parasitology Research.
[12] Javad Shokri,et al. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice , 2011, International journal of nanomedicine.
[13] S. Jarudilokkul,et al. Preparation of chitosan nanoparticles for encapsulation and release of protein , 2011 .
[14] M. Heimesaat,et al. Immunology of Toxoplasma gondii , 2011, Immunological reviews.
[15] M. Heimesaat,et al. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood–brain barriers , 2011, Journal of drug targeting.
[16] U. Vogel,et al. Distribution of silver in rats following 28 days of repeated oral exposure to silver nanoparticles or silver acetate , 2011, Particle and Fibre Toxicology.
[17] I. Yu,et al. Subchronic oral toxicity of silver nanoparticles , 2010, Particle and Fibre Toxicology.
[18] M. Thanou,et al. Biodegradation, biodistribution and toxicity of chitosan. , 2010, Advanced drug delivery reviews.
[19] Dakrong Pissuwan,et al. Destruction and control of Toxoplasma gondii tachyzoites using gold nanosphere/antibody conjugates. , 2009, Small.
[20] R. Müller,et al. The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis , 2009, Journal of drug targeting.
[21] M. Eissa,et al. Synthesis and evaluation of some pyrimidine analogs against toxoplasmosis , 2008, Medicinal Chemistry Research.
[22] Dakrong Pissuwan,et al. A golden bullet? Selective targeting of Toxoplasma gondii tachyzoites using antibody-functionalized gold nanorods. , 2007, Nano letters.
[23] Kemin Wang,et al. Preparation and antibacterial activity of Fe3O4@Ag nanoparticles , 2007 .
[24] L. Garcia. Macroscopic and Microscopic Examination of Fecal Specimens , 2007 .
[25] O. Pardini,et al. Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent. , 2006, International journal of pharmaceutics.
[26] H. B. Liu,et al. Biosynthesis and characterization of Ti/Ni bimetallic nanoparticles , 2006 .
[27] R. Pandey,et al. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. , 2006, The Indian journal of chest diseases & allied sciences.
[28] Tetsuya Osaka,et al. THE STUDY OF ANTIMICROBIAL ACTIVITY AND PRESERVATIVE EFFECTS OF NANOSILVER INGREDIENT , 2005 .
[29] C. Roberts,et al. Triazine Inhibits Toxoplasma gondii Tachyzoites In Vitro and In Vivo , 2005, Antimicrobial Agents and Chemotherapy.
[30] A. Nikolić,et al. Effectiveness of spiramycin in murine models of acute and chronic toxoplasmosis. , 2005, International journal of antimicrobial agents.
[31] Jing-huai Fang,et al. The study of deposited silver particulate films by simple method for efficient SERS , 2005 .
[32] M. Kurowski,et al. Atovaquone Maintenance Therapy Prevents Reactivation of Toxoplasmic Encephalitis in a Murine Model of Reactivated Toxoplasmosis , 2004, Antimicrobial Agents and Chemotherapy.
[33] D. Buxton,et al. Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep. , 2004, Vaccine.
[34] J. de Braekeleer,et al. Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. , 2003, International journal of pharmaceutics.
[35] Bing Xu,et al. Presenting Vancomycin on Nanoparticles to Enhance Antimicrobial Activities , 2003 .
[36] Jayanth Panyam,et al. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.
[37] Helmut Hahn,et al. Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis , 2001, Antimicrobial Agents and Chemotherapy.
[38] L. Weiss,et al. Toxoplasma gondii: from animals to humans. , 2000, International journal for parasitology.
[39] F. Derouin,et al. Cotrimoxazole for prenatal treatment of congenital toxoplasmosis? , 2000, Parasitology today.
[40] K. Ismail,et al. Novel triazolo[4,3-a]quinazolinone and bis-triazolo[4,3-a:4,3'-c]quinazolines: synthesis and antitoxoplasmosis effect. , 1999, Farmaco.
[41] D. Mazier,et al. Encephalitozoon intestinalis: humoral responses in interferon-gamma receptor knockout mice infected with a microsporidium pathogenic in AIDS patients. , 1998, Experimental parasitology.
[42] B. Luft,et al. Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice , 1986, Antimicrobial Agents and Chemotherapy.
[43] T. Asai,et al. Transmission and scanning electron microscopy of host cell entry by Toxoplasma gondii. , 1977, The American journal of pathology.
[44] E. R. Dalton. Statistics in Small Doses , 1972 .
[45] W. Castle. Statistics in small doses , 1972 .
[46] C. Betsch,et al. Scanning-beam electron microscopy of selected microorganisms. , 1970, The Journal of infectious diseases.
[47] E. De,et al. Spiramycin therapy of experimental toxoplasmosis in mice , 1958 .